Business Context and Reporting Period
This Form 6-K filing by GSK plc (GSK) reports a transaction in the company's own shares. The filing date is April 29, 2025, covering a share repurchase executed on April 28, 2025. The transaction was conducted through Citigroup Global Markets Limited as part of an existing buyback programme established via a non-discretionary agreement on February 24, 2025.
Key Financial Metrics
The filing details a specific share repurchase event rather than comprehensive financial statements. Key metrics for this transaction include:
- Shares Purchased: 688,703 ordinary shares.
- Price Range: Lowest price paid was 1,394.00 GBp; highest price paid was 1,413.00 GBp.
- Average Price: Volume-weighted average price (VWAP) was 1,405.53 GBp.
- Treasury Holdings: Following this purchase, GSK holds 203,419,458 ordinary shares in treasury.
- Shares in Issue: 4,111,821,920 ordinary shares (excluding treasury shares).
- Voting Rights: Total voting rights stand at 4,111,821,920.
The filing text does not provide values for revenue, profit, cash flow, margins, or debt levels.
Material Changes
Since the commencement of the current buyback programme on February 24, 2025, GSK has purchased an aggregate of 34,349,155 ordinary shares. The April 28 transaction represents a continuation of this programme, executed entirely on the London Stock Exchange (XLON). No purchases were made on CBOE Europe venues (BATE or CHIX) during this specific reporting period.
Outlook, Risks, and Management Commentary
The purchased shares are to be held as Treasury shares. The company includes a standard cautionary statement regarding forward-looking statements, noting that actual results may differ materially from projections due to risks and uncertainties. These risks are referenced as being described in the "Risk factors" section (pages 277 to 285) of the GSK 2024 Annual Report on Form 20-F. No specific guidance or management commentary regarding future financial performance is included in this filing.
Investor Verification Checklist
- Verify the total number of shares purchased under the buyback programme since February 24, 2025 (stated as 34,349,155).
- Confirm the current number of shares in issue and treasury holdings for accurate voting right calculations (4,111,821,920 voting rights).
- Review the GSK 2024 Annual Report on Form 20-F (pages 277-285) for detailed risk factors referenced in the cautionary statement.
- Monitor future 6-K filings for updates on the remaining capacity or status of the non-discretionary buyback agreement.